← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Various alimentary tract and metabolism products
teduglutide
A16AX08
Forms & Strengths
- Lyophilized powder for subcutaneous injection: 5 mg per vial
Adult Dosing
- Short Bowel Syndrome: 0.05 mg/kg subcutaneously once daily
Pediatric Dosing
- Pediatric patients 1 year and older: 0.05 mg/kg subcutaneously once daily
Indications
- Treatment of short bowel syndrome (SBS) in patients dependent on parenteral support
Mechanism of Action
- Glucagon-like peptide-2 (GLP-2) analog that increases intestinal absorption of fluids and nutrients
- Promotes regeneration and enhances structural adaptation of the intestinal mucosal epithelium
Contraindications
- Active gastrointestinal malignancy
- History of gastrointestinal, pancreatic, or colorectal neoplasia within the past 5 years
- Known hypersensitivity to teduglutide
Adverse Reactions
- Abdominal pain
- Nausea
- Vomiting
- Abdominal distension
- Injection site reactions
- Fluid overload
- Upper respiratory tract infection
Drug Interactions
- Concomitant oral medications with narrow therapeutic index require monitoring due to potential changes in absorption
- Parenteral nutrition reduction may alter clearance of renally eliminated drugs
Curated Content: Needs Vetting Before Put to Clinical Use